NEW YORK (GenomeWeb) – German-Spanish DNA amplification and sequencing firm Sygnis today announced it has signed a patent transfer agreement providing certain rights to its Double Switch technology to Systasy Bioscience.

The Double Switch technology is for the qualitative and quantitative detection of protein-protein interactions, and as part of the deal, Systasy has purchased the patent covering the technology in a split version (Split TEV) for use with its EXTassay platform.

Sygnis retains the rights to Double Switch in its full-length version (Full TEV).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.